Strategic Report ANNUAL REPORT AND ACCOUNTS 2016 FINANCIAL REVIEW The financial results of the year reflect the Groups sustainable model of deploying capital into our portfolio of Group controlled businesses at the right pace.
During 2016, $108.2 million was invested into new and existing portfolio companies.
This included $60.2 million from subsidiary fundraisings including $6.0 million raised in 2015 but received from investors in 2016, with $48.5 million coming from third-party investment, to further accelerate the development of four of the Groups existing companies, ABLS II, Federated Wireless, Precision Biopsy and HawkEye 360.
In addition to these fundraisings, $48.0 million was invested by the Group into new and other existing portfolio companies.
Consolidated Statement of Comprehensive Loss For the years ended 31 December 2016 2015 $ 000 $ 000 Revenue 2,664 3,300 Cost of revenue 5,563 3,925 Selling, general and administrative expenses 55,484 46,888 Research and development expenses 55,292 49,209 Finance cost, net 15,267 1,267 Other comprehensive income 208 46 Total comprehensive loss 128,734 97,943 of which attributable to: Equity holders of the parent 96,125 77,752 Non-controlling interests 32,609 20,191 Revenue decreased by $0.6 million, to $2.7 million in 2016 2015: $3.3 million.
This decrease is mainly attributable to the lower product revenue at RF Biocidics.
The revenue in the early stage companies segment decreased to $0.6 million in 2016 2015: $1.1 million.
Cost of revenue increased by $1.6 million to $5.6 million 2015: $3.9 million, reflecting write offs of inventory at RF Biocidics and CryoXtract.
Selling, general and administrative SG&A expenses increased by $8.6 million, to $55.5 million, for the year ended 31 December 2016 2015: $46.9 million, largely due to the overall growth of the Group.
Of this increase, $6.5 million relates to an increase in personnel expenses reflecting the increase in headcount and salaries as well as an increase in non-cash share-based compensation expense by $1.7 million.
The increase is also attributed to higher non-cash depreciation, amortisation and impairment charges which were higher by $3.8 million compared to prior year, offset by a $0.8 million decrease in sales and marketing cost, a $1.0 million decrease in occupancy and related expenses, and a $0.7 million decrease in professional services.
R&D expenses increased by $6.1 million to $55.3 million for the year ended 31 December 2016 2015: $49.2 million.
The increase is attributed to the overall growth of the Groups research and development activities, reflecting the acceleration of activities at a few companies as supported by third party financing rounds in 2015 and 2016 and ramping up full scale of R&D activities of companies created in late 2014 and into 2015.
Finance cost, net increased by $14.0 million to $15.3 million in 2016 2015: $1.3 million primarily due to the finance cost from fair value accounting adjustment of the subsidiary preferred shares liability balance of 27 ANNUAL REPORT AND ACCOUNTS 2016 FINANCIAL REVIEW CONTINUED $17.6 million, offset by exchange rate profits of $1.3 million and interest income, net of interest expense, of $1.0 million.
As a result of the above discussed factors, total comprehensive loss increased by $30.8 million to $128.7 million for the year ended 31 December 2016 2015: $97.9 million.
Total comprehensive loss for the year attributed to the equity holders of the Group was $96.1 million 2015: $77.8 million and $32.6 million 2015: $20.2 million was attributable to the owners of non-controlling interests.
Consolidated Statement of Financial Position As of 31 December 2016 2015 $ 000 $ 000 Non-current assets 38,282 92,784 Current assets 232,007 158,427 Total assets 270,239 251,211 Non-current liabilities 720 863 Current liabilities 155,402 108,974 Equity 114,117 141,374 Total liabilities and equity 270,239 251,211 Significant  events and business developments reflected in the Companys financial position at year end include: Property and equipment decreased by $2.3 million to $31.9 million as at 31 December 2016 2015: $34.2 million, mainly reflecting depreciation expense of $5.7 million and impairment charges of $0.4 million, offset by purchases of approximately $3.8 million, of which $1.8 million relates to STT: Intangible assets as of 31 December 2016 decreased by $1.6 million to $2.8 million 2015: $4.4 million mainly as a result of amortisation expense of $0.9 million and impairment charges of $1.0 million, offset by additions of $0.3 million in capitalised development costs, acquired licenses and software assets: Other investments, non-current decreased to $2.7 million 2015: $51.5 million reflecting the investment of excess cash into fixed income government and corporate securities that have maturities longer than twelve months: Cash and cash equivalents increased by $103.6 million to $209.2 million at 31 December 2016 from $105.6 million at 31 December 2015.
The increase is mainly attributed to $128.1 million of cash from financing activities from the Companys equity placing in December 2016 and proceeds from subsidiary financing rounds, and $70.7 million cash from investing activities mainly reflecting the conversion of fixed income security investments into cash and cash equivalents.
The overall increase in cash and cash equivalents was offset by $95.2 million of net cash used in operations: Other investments, current decreased to $14.2 million 2015: $37.6 million reflecting the investment of excess cash into fixed income government and corporate securities that have maturities shorter than twelve months: 28 Strategic Report ANNUAL REPORT AND ACCOUNTS 2016 FINANCIAL REVIEW CONTINUED Inventories increased by $1.1 million to $2.6 million as at 31 December 2016 2015: $1.5 million reflecting the purchases of inventories of $2.1 million, offset by cost of goods sold and other obsolescence charges of $1.0 million: Trade and other receivables decreased by $1.4 million to $5.9 million at 31 December 2016 2015: $7.3 million as a result of decrease in prepaid and other current assets of $0.7 million mainly from write off of advance payments for inventory units at RFB, plus a net decrease of $0.7 million in trade receivables: Subscription receivable of $6.0 million reflecting the second tranche of the Series A preferred round at Precision Biopsy due by third party investors was collected in 2016 and the balance decreased to nil as at 31 December 2016 2015: $6.0 million : The loans balance, current and non-current, decreased to $0.1 million as of 31 December 2016 2015: $0.3 million reflecting the repayment of the principal balance by CryoXtract Instruments: Subsidiary preferred shares increased by $46.8 million to $140.9 million as of 31 December 2016 2015: $94.1 million as a result of Series A preferred rounds of $29.2 million at Federated Wireless, Precision Biopsy and HawkEye 360 in 2016 as well as the fair value adjustment for the year of $17.6 million primarily at SciFluor and STT: Deferred revenue remained consistent at $0.5 million as of 31 December 2016, when compared to $0.4 million in prior year: and Share capital and premium increased by $1.4 million to a combined $160.7 million at 31 December 2016 2015: $159.3 million primarily due to exercises of stock options under the U. S. Stock Option Plan.
Merger reserve increased by $77.9 million due to the net proceeds from the Companys equity placing in December 2016.
The increase in accumulated deficit of $96.6 million to $289.4 million 2015: 192.8 million reflected the net comprehensive loss attributable to equity holders of the Group for the year of $96.1 million 2015: $77.8 million and the effect from change in non-controlling interest of $6.2 million 2015: $3.2 million, offset by the share-based compensation expense charge for the year of $5.9 million 2015: $3.2 million.
Consolidated Statement of Cash Flows For the years ended 31 December 2016 2015 $ 000 $ 000 Net cash outflow from operating activities 95,220 81,918 Net cash inflow outflow from investing activities 70,729 74,999 Net cash inflow from financing activities 128,087 38,397 Net increase decrease increase in cash and cash equivalents 103,596 118,520 Cash and cash equivalents in the beginning of the year 105,555 224,075 Cash and cash equivalents at the end of the year 209,151 105,555 29 ANNUAL REPORT AND ACCOUNTS 2016 FINANCIAL REVIEW CONTINUED The Groups net cash outflow from operating activities of $95.2 million in 2016 2015: $81.9 million was primarily due to the net operating losses for the year of $113.7 million, offset by the net effect from movement in working capital of $0.5 million, adjustment for non-cash items such as depreciation, amortisation, impairments and share-based expenses of $16.4 million and interest received net of paid and other finance charges of $1.6 million.
The Group had a net cash inflow from investing activities of $70.7 million in 2016 2015: outflow of $75.0 million mainly reflecting the disposal of fixed income investment securities of $72.3 million and $2.5 million from disposal of an equity accounted investee, offset by purchases or property and equipment net of disposals of $3.8 million, and purchases of intangible assets net of disposals of $0.3 million.
The Groups net cash inflow from financing activities of $128.1 million in 2016 2015: $38.4 million primarily reflects $78.1 million of net proceeds from the Companys equity placing in December 2016, $49.0 million proceeds from subsidiary financing rounds in ABLS II, Federated Wireless, HawkEye 360 and Precision Biopsy, and $1.2 million from exercises of stock options, offset by $0.2 million repayment of notes payable.
The Groups strategy is to maintain healthy, highly liquid cash balances that are readily available to support the activities of its subsidiaries by providing working capital, maintaining the level of research and development activities required to achieve the set milestone goals, and acquiring capital equipment where necessary to support research and development activities.
To further minimise its exposure to risks the Group does not maintain any material borrowings or cash balances in foreign currency.
